Psychedelic Spotlight News

MindMed Financial Results & Business Update Q2 2021 ( Where Does MNMD/MMED Go From Here?)

MindMed's Financial Results & Business Update for Q2 2021 are out! In this episode, we'll discuss MindMed, ( MMED: NEO), (MNMD: NASDAQ), (MMQ: FRA), who recently announced their Q2 financials and gave a business update. This was an important, transitional quarter for the company for several reasons. First, and perhaps most significantly, during Q2, co-founder JR Rahn stepped down as CEO, being replaced by Robert Barrow, who was previously Chief Development Officer. Second, in terms of progress in the mission to heal mental health, MindMed made several strides in this quarter, which we'll discuss today. Pertinent links: MindMed's CEO Jr Rahn Steps Down: https://thepsychedelicinvestor.com/2021/06/09/mindmed-announces-chief-executive-officer-transition/ Project Angie Update: https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/ MindMed's Collaboration with NextStage Therapeutics: https://mindmed.co/news/press-release/mindmed-announces-launch-of-collaboration-with-nextage-therapeutics-brain-targeting-liposome-system/ MindMed's Pharmacogenetic Study: https://thepsychedelicinvestor.com/2021/05/26/mindmed-and-liechti-lab-in-basel-switzerland-publish-first-pharmacogenetic-data-on-lsd-to-help-guide-personalized-dosing/ MMED's Q2 Financial Results & Business Update: https://thepsychedelicinvestor.com/2021/08/13/mindmed-announces-2021-q2-financial-results-cash-balance-of-157-usd-million-195-cad-million-to-execute-on-diverse-clinical-pipeline/ Enjoy the episode! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedStock #MNMD

Interview With Henri Sant-Cassia

Podcasts

In today’s episode of the Psychedelic Spotlight podcast, we spotlight Henri Sant-Cassia, Co-Founding Partner of The Conscious Fund, a leading investment fund in the medicinal psychedelics industry, focused on early stage ventures and psychedelic medicine that are helping to deliver better outcomes for mental health, addiction and pain.

How Ayahuasca and Volcanic Disaster Pulled Microdosing Mentor Laura Dawn Out of the ‘Psychedelic Closet’

Business, Culture, Microdosing

The Psychedelic Spotlight podcast guest also addresses criticism that she is a white woman working with sacred plant medicine, and how that inspired her next non-profit venture.

Psychedelic Business Spotlight: August 13, 2021

Business, Stock Reports

This week in psychedelic business news: Psychedelics in development to treat eye diseases and stroke; companies gear up for new clinical trials investigating psychedelics for general anxiety, chronic pain, and eating disorders.

Mydecine Joins the BIG LEAGUES! MYCO + Johns Hopkins to treat smoking addiction with MAGIC MUSHROOMS

Videos

Mydecine (OTC: MYCOF, NEO: MYCO) is an aspiring psychedelics medicine company that aims to use psilocybin, the active ingredient in magic mushrooms, to treat smoking addiction and PTSD. First, they are using pure psilocybin called MYCO-001, but eventually, Mydecine wants to use a proprietary, shorter-lasting compound called MYCO-004. While Mydecine probably isn't considered as being in the top tier of psychedelic researchers (yet at least), they recently have teamed up with Johns Hopkins University and Dr. Matthew Johnson, an institution and individual widely considered to be leaders in the field. With this partnership, Mydecine may become a leader among the "shroom stocks". Specifically, Mydecine and Johns Hopkins are joining forces to run phase 2 and 3 clinical trials treating smoking addiction with psilocybin, though they may expand their partnership in the future. Is Mydecine (MYCO:NEO) (MYCOF: OTC ) one of the best penny stocks of 2021? Can magic mushrooms treat smoking addiction? Watch the episode to find out! Waht do you guys think about the Mydecine partnering up with Johns Hopkins University? Links: https://uploads-ssl.webflow.com/5ee12ebc38f9e96f52217dd1/610efbd58b2b1755e49eb55b_MYCO_Presentation_8.6.21-compressed.pdf https://www.hopkinsmedicine.org/profiles/details/matthew-johnson Enjoy the episode! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MYDECINE #MYCO #JOHNSHOPKINS

What Is Salvia Divinorum and How Can the Psychedelic Help Humanity?

Research

Take a deep dive into the history, effects, and benefits of this psychoactive plant that is still largely under the radar as interest in psychedelics explodes.

Nova Mentis Reaches Milestone Developing Psilocybin to Treat Autism

Business, Research

Nova Mentis says that psilocybin could be a novel, first-in-class treatment for a brain disorder that leads to learning disabilities and behavioral problems.